CARLYLE | Jotup

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

Retrieved on:

Monday, April 1, 2024

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).

Key Points:

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).
As part of the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, will have the lead role in the operational execution and management of the planned clinical trials, focused on accelerating Teva’s ICS-SABA (TEV-‘248) clinical research program.
Teva will recognize the funding as a reduction in research and development expenses and will retain full rights to the Company’s ICS/SABA program.
“Bridging together Teva's deep therapeutic expertise with Launch Therapeutics' profound clinical and operational expertise generates value to execute and accelerate this program.

SER Welcomes New Investment from TA to Accelerate Growth

Retrieved on:

Thursday, March 21, 2024

Data Management, Technology, Apps, Applications, Artificial Intelligence, Software, Microsoft, DACH, Organization, ECM, Growth, Partnership, Salesforce, SAP, TA Associates, Enterprise content management, Multimedia

SER (the “Company”), a leading global Intelligent Content Automation (“ICA”) software vendor in the Enterprise Content Management (“ECM”) market, today announced that TA Associates (“TA”), a leading global private equity firm, has agreed to make a strategic growth investment in the Company.

Key Points:

SER (the “Company”), a leading global Intelligent Content Automation (“ICA”) software vendor in the Enterprise Content Management (“ECM”) market, today announced that TA Associates (“TA”), a leading global private equity firm, has agreed to make a strategic growth investment in the Company.
SER and Carlyle, an investor in SER since 2018, welcome TA as the new lead investor.
View the full release here: https://www.businesswire.com/news/home/20240321414321/en/
“We are delighted to welcome TA to SER as an investor and we are proud that they share our perspective on the significant opportunities ahead for our business,” said Dr. John Bates, CEO of SER.
We are delighted to partner with TA as the new lead investor in SER as the Company enters the next phase of its growth journey.”
The transaction is subject to customary regulatory approvals.

Red Apple Stores Unveils Grand Opening of Newly Rebranded Store in Carlyle, SK!

Retrieved on:

Thursday, April 4, 2024

The Red Apple, The Bargain, Golden Joystick Awards, Metropolitan Stores, Red, Red apple

MISSISSAUGA, ON, April 4, 2024 /CNW/ - Red Apple Stores is thrilled to announce the grand opening of their newly rebranded store at 203 Main St in Carlyle, Saskatchewan.

Key Points:

MISSISSAUGA, ON, April 4, 2024 /CNW/ - Red Apple Stores is thrilled to announce the grand opening of their newly rebranded store at 203 Main St in Carlyle, Saskatchewan.
The updated Red Apple Store aims to provide customers with a revitalized shopping experience while maintaining the incredible savings and convenience they have come to expect.
Brendan Proctor, CEO of Red Apple Stores, expressed his excitement about revealing the rebranded store to the Carlyle community.
The entire Red Apple team invites everyone to join them in celebrating the Grand Opening of the newly renovated store in Carlyle, Saskatchewan.

Involta Appoints John Scarry as Chief Revenue Officer

Retrieved on:

Tuesday, April 2, 2024

Public sector, Knowledge, Growth, Equinix

CLEVELAND, April 2, 2024 /PRNewswire/ -- Involta, a Carlyle portfolio company and prominent national provider of data center and cloud infrastructure and services, announced today that John Scarry has joined the company as Chief Revenue Officer (CRO). Scarry will leverage decades of industry experience to lead Involta's efforts in the growth and expansion of revenue streams to meet the rising demands of enterprise IT infrastructure and services.

Key Points:

CLEVELAND, April 2, 2024 /PRNewswire/ -- Involta, a Carlyle portfolio company and prominent national provider of data center and cloud infrastructure and services, announced today that John Scarry has joined the company as Chief Revenue Officer (CRO).
"John brings a wealth of knowledge, relationships and success in driving strategies to deliver growth and expansion," stated Brett Lindsey, Involta CEO.
"It is an exciting time to join Involta – the potential to attract new and support current clients is significant," said John Scarry, CRO.
John will be focused on the strategic growth of Involta's data center and cloud infrastructure footprint, shaping revenue generation and ensuring client success.

AZZ Inc. Announces CFO Succession Plan

Retrieved on:

Tuesday, March 26, 2024

Culture, Boston Scientific, Philip, Business administration, Senior, AZZ, Retirement, Management

While his retirement is not imminent, his work ethic and passion for the Company and its people will be hard to replace.

Key Points:

While his retirement is not imminent, his work ethic and passion for the Company and its people will be hard to replace.
I truly appreciate his advance notice that will ensure a smooth and well-planned transition."
AZZ strives to promote a 'next person up' culture to ensure continuity in many of our key positions.
He has broad expertise in both domestic and international companies across a wide variety of industries," concluded Mr. Ferguson.

Carlyle Secured Lending, Inc. Names Justin Plouffe CEO and Member of the Board of Directors

Retrieved on:

Monday, March 4, 2024

Columbia Law School, Investment, CSL, Princeton University, CFA, Columbia Law Review, Trustee, CLO, Series 7, Rope, Ropes & Gray, Management

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (“CSL”) (NASDAQ: CGBD) today announced that Justin Plouffe has been named President, Chief Executive Officer (CEO), and member of the Board of Directors, effective immediately.

Key Points:

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (“CSL”) (NASDAQ: CGBD) today announced that Justin Plouffe has been named President, Chief Executive Officer (CEO), and member of the Board of Directors, effective immediately.
Mr. Plouffe is a Managing Director and the Deputy Chief Investment Officer for Global Credit at Carlyle.
He focuses on investing across Carlyle’s credit strategies, capital formation as well as managing the overall Global Credit platform.
Linda Pace, Chair of the Board of Directors at Carlyle Secured Lending said, “The Board is delighted that Justin Plouffe is joining CSL as President and CEO.

Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead Sciences

Retrieved on:

Thursday, February 29, 2024

Lung cancer, Gilead Sciences, Pharmaceutical industry

London, UK and New York, USA, February 29, 2024 - Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced a strategic development financing agreement with Gilead Sciences.

Key Points:

London, UK and New York, USA, February 29, 2024 - Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced a strategic development financing agreement with Gilead Sciences.
The financing agreement will provide up to $210 million in funding to support select clinical studies of Trodelvy® (sacituzumab govitecan-hziy), within non-small cell lung cancer.
As part of the agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, and Gilead have entered into a clinical collaboration agreement that establishes a Joint Steering Committee throughout development.
Gilead retains full rights to Trodelvy and, if development is successful, Abingworth would receive a fixed payment upon regulatory approval of a pre-defined label expansion, as well as royalty payments based on U.S. Trodelvy net sales within the specific tumor type.

Opthea Reports Half-Year Financial Results and Business Updates

Retrieved on:

Wednesday, February 28, 2024

MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced financial results for the six months ended December 31, 2023 and highlighted recent corporate and clinical updates.

Key Points:

We recently announced the completion of enrollment in our first pivotal Phase 3 trial (COAST), in combination with EYLEA® (aflibercept),” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea.
Peter Lang, Chief Financial Officer of Opthea, added, “We are excited about Opthea’s progress.
Top-line Phase 3 results from the COAST and ShORe trials expected by mid-CY 2025.
In August 2023, Opthea successfully completed a private placement and rights equity offering raising A$90 million (US$58 million) in Australia.

Saama Announces Industry Veteran Bhaskar Sambasivan as New CEO

Retrieved on:

Tuesday, February 20, 2024

Saama today announced the appointment of Bhaskar Sambasivan as Chief Executive Officer.

Key Points:

Saama today announced the appointment of Bhaskar Sambasivan as Chief Executive Officer.
An industry veteran within life sciences, Bhaskar brings a deep understanding of how technology innovations are driving today’s advances in science and medicine.
As Saama CEO, Bhaskar will oversee the continued growth of the business as well as innovation in Saama’s AI-enabled SaaS products and solutions that support the full spectrum of clinical development within the life sciences industry.
Saama is committed to fostering innovation and supporting the complex needs of its customers.

Ontra Welcomes Leslie Olsen as Chief Marketing Officer

Retrieved on:

Wednesday, March 6, 2024

SAN, C2FO, Marketing, Intelligence, Growth, KKR, International political economy, University, San Francisco Bay Area, ABM, Science, Fundbox, PEI, Cryptocurrency

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Ontra, the leading provider of AI-powered legal technology solutions for the world's most prominent private capital investment firms, today announced the appointment of Leslie Olsen as Chief Marketing Officer.

Key Points:

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Ontra, the leading provider of AI-powered legal technology solutions for the world's most prominent private capital investment firms, today announced the appointment of Leslie Olsen as Chief Marketing Officer.
Leslie brings over 20 years of experience as a deeply customer-centric marketing leader focused on delivering profitable growth.
Leslie will oversee strategic marketing for Ontra's Legal Operating System, which leverages artificial intelligence to automate critical legal workflows across fundraising, portfolio investment, and fund operations.
"Throughout my career, I've been drawn to companies that address critical pain points for customers in unique and innovative ways," said Leslie Olson, Chief Marketing Officer at Ontra.